동국제약

086450KOSDAQ의약품 제조업

69.5 / 100

Reference Date: 2026-04-13

Financial Score27.5 / 40

News Sentiment14.0 / 25

Momentum18.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE significantly exceeds the industry average and the debt ratio is very low with excellent financial health is also solid. Surged 39.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Dongkook Pharmaceutical, established in 1968, aims to become South Korea's leading total healthcare group by focusing on new product development and global market expansion. The company offers a wide range of products in over-the-counter drugs, specialty pharmaceuticals, and healthcare sectors, and has successfully exported its products to countries such as China, Japan, and Europe.

Number of Employees

1,306people

Average Salary

67.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

17.22Industry Average 14.803.0Point

Higher than industry avg (caution)

PBR

1.52Industry Average 1.042.5Point

Higher than industry avg (caution)

ROE

10.25Industry Average 4.427.0Point

2.3x industry avg (excellent)

Debt Ratio

4.16Industry Average 11.986.5Point

Half of industry avg (excellent)

Trend 2023~20258.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲12.6% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲20.2% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 9.7% (improving, 3yr)

Detailed News Sentiment

12 totalPositive 2Neutral 5Negative 0Average Sentiment Score 60

Detailed Momentum

52-week position6.0Point

52w upper range (71%)

Current 25,600Won52-week high 29,90052-week low 15,050

1-month return6.0Point

1m +39.13% (strong rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-20
Neutral정기주주총회결과2026-03-20